MicrosoftTeams-image (5).png
Urgent Care Centers Market Booming at 4.4% CAGR to Reach US$ 50.3 Mn by 2031 | Global Analysis by TMR
15 mai 2023 12h30 HE | Transparency Market Research
Wilmington, Delaware, United States, May 15, 2023 (GLOBE NEWSWIRE) -- The global urgent care centers market size was worth US$ 32.5 Mn in 2021 and is likely to reach a value of over US$ 50.3 Mn by...
mrf.jpg
Rapid Diagnostics Market Size to Hit USD 177.37 Billion by 2032 at 21.3% CAGR – Report by Market Research Future (MRFR)
15 mai 2023 10h30 HE | Market Research Future
New York, USA, May 15, 2023 (GLOBE NEWSWIRE) -- Rapid Diagnostics Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Rapid Diagnostics Market...
sphericalinsightsoptionblue.png
Global Diagnostic Catheters Market Size To Worth USD 6.8 Billion By 2030 | CAGR of 6.2%
15 mai 2023 08h15 HE | SPHERICAL INSIGHTS LLP
New York, United States , May 15, 2023 (GLOBE NEWSWIRE) -- The Global Diagnostic Catheters Market Size to grow from USD 4.1 billion in 2021 to USD 6.8 billion by 2030, at a Compound Annual Growth...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert
10 mai 2023 03h01 HE | Mainz BioMed NV
Combination of DNA biomarkers with microbiome biomarkers has potential to enhance technical profile of novel pancreatic cancer screening test Joint research project to discover disease specific...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners
03 mai 2023 03h01 HE | Mainz BioMed NV
Eurofins GeLaMed to provide test kit processing of ColoAlert® through Germany BERKELEY, Calif. and MAINZ, Germany, May 03, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed to Participate in Digestive Disease Week 2023
01 mai 2023 03h01 HE | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, May 01, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
27 avr. 2023 03h01 HE | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 27, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal
26 avr. 2023 03h01 HE | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 26, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
About Mind.Px™
Mindera Health™ Announces Coverage with Evidence Project with Highmark, Inc. to Advance Moderate-to-Severe Psoriasis Patient Care and Reduce Specialty Drug Spending
11 avr. 2023 09h00 HE | Mindera Health
San Diego, CA, April 11, 2023 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of Mind.Px, the first realization of precision medicine in psoriasis, has initiated a coverage with evidence project...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Provides Full Year 2022 Financial Results
10 avr. 2023 03h01 HE | Mainz BioMed NV
ColoAlert Revenue Increases 130% Year over Year Year End Cash Balance of $17.1 Million BERKELEY, Calif. and MAINZ, Germany, April 10, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V....